These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23720157)

  • 1. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
    Colbert LE; Fisher SB; Hardy CW; Hall WA; Saka B; Shelton JW; Petrova AV; Warren MD; Pantazides BG; Gandhi K; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
    Cancer; 2013 Sep; 119(17):3148-55. PubMed ID: 23720157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer.
    Li X; Guo J; Ding AP; Qi WW; Zhang PH; Lv J; Qiu WS; Sun ZQ
    Technol Cancer Res Treat; 2017 Aug; 16(4):428-434. PubMed ID: 27432118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
    Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby DA; El-Rayes BF; Staley CA; Farris AB; Maithel SK
    Cancer; 2013 Sep; 119(17):3242-50. PubMed ID: 23719746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
    Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
    Maithel SK; Coban I; Kneuertz PJ; Kooby DA; El-Rayes BF; Kauh JS; Sarmiento J; Staley CA; Volkan Adsay N
    Ann Surg Oncol; 2011 Sep; 18(9):2699-705. PubMed ID: 21360249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of mixed lineage kinase domain-like protein expression in the survival of patients with gastric caner.
    Ertao Z; Jianhui C; Kang W; Zhijun Y; Hui W; Chuangqi C; Changjiang Q; Sile C; Yulong H; Shirong C
    Tumour Biol; 2016 Oct; 37(10):13679-13685. PubMed ID: 27473085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Cros J; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Eur J Cancer; 2013 Aug; 49(12):2643-53. PubMed ID: 23726265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed lineage kinase domain-like protein is a prognostic biomarker for cervical squamous cell cancer.
    Ruan J; Mei L; Zhu Q; Shi G; Wang H
    Int J Clin Exp Pathol; 2015; 8(11):15035-8. PubMed ID: 26823841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients.
    He L; Peng K; Liu Y; Xiong J; Zhu FF
    Onco Targets Ther; 2013; 6():1539-43. PubMed ID: 24204164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
    Hall WA; Petrova AV; Colbert LE; Hardy CW; Fisher SB; Saka B; Shelton JW; Warren MD; Pantazides BG; Gandhi K; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Volkan Adsay N; Curran WJ; Landry JC; Maithel SK; Yu DS
    Oncogene; 2014 Nov; 33(47):5450-6. PubMed ID: 24276239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.
    Ning Z; Wang A; Liang J; Liu J; Zhou T; Yan Q; Wang Z
    Int J Clin Exp Pathol; 2014; 7(5):2462-9. PubMed ID: 24966957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma.
    Elebro J; Heby M; Gaber A; Nodin B; Jonsson L; Fristedt R; Uhlén M; Jirström K; Eberhard J
    J Transl Med; 2014 Oct; 12():289. PubMed ID: 25323550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
    Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
    Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
    Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
    Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.
    Aydin D; Sendur MA; Kefeli U; Unal OU; Tastekin D; Akyol M; Tanrikulu E; Ciltas A; Ustaalioglu BB; Uysal M; Esbag O; Yazilitas D; Tanrıverdi O; Bilici A; Arpaci E; Berk V; Yetisyigit T; Ozdemir NY; Oztop I; Alacacioglu A; Aydin O; Ozcelik M; Yildirim E; Dinc N; Gumus M
    Clin Colorectal Cancer; 2017 Sep; 16(3):220-227. PubMed ID: 27670893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
    Liu XD; Zhang ZW; Wu HW; Liang ZY
    Pathol Res Pract; 2021 Jan; 217():153313. PubMed ID: 33341545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
    Huffman BM; Jin Z; Yadav S; Patel S; Nagorney DM; Truty MJ; McWilliams RR; Halfdanarson TR; Mahipal A
    Clin Colorectal Cancer; 2019 Sep; 18(3):218-225. PubMed ID: 31178274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.
    Huang L; Balavarca Y; van der Geest L; Lemmens V; Van Eycken L; De Schutter H; Johannesen TB; Zadnik V; Primic-Žakelj M; Mägi M; Grützmann R; Besselink MG; Schrotz-King P; Brenner H; Jansen L
    BMC Med; 2019 Mar; 17(1):66. PubMed ID: 30905320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
    Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
    Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
    Di Narzo AF; Tejpar S; Rossi S; Yan P; Popovici V; Wirapati P; Budinska E; Xie T; Estrella H; Pavlicek A; Mao M; Martin E; Scott W; Bosman FT; Roth A; Delorenzi M
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25246611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.